Listed

Protara Therapeutics, Inc.

TARANasdaqCIK 1359931HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$23.3m, Q2 FY2026
Net income−$21.7m, Q2 FY2026
Protara Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m6.2Research and development, Q3 FY2023, three months to 2023-09-30$6.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figure6.4Research and development, Q4 FY2023, three months to 2023-12-31$6.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-05, accession 0001213900-25-020368. Derived: 12-month figure less the 9-month figure.Report this figure7.7Research and development, Q1 FY2024, three months to 2024-03-31$7.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure6.4Research and development, Q2 FY2024, three months to 2024-06-30$6.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0001213900-25-073942.Report this figure8.1Research and development, Q3 FY2024, three months to 2024-09-30$8.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure9.5Research and development, Q4 FY2024, three months to 2024-12-31$9.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-10, accession 0001213900-26-025433. Derived: 12-month figure less the 9-month figure.Report this figure9.1Research and development, Q1 FY2025, three months to 2025-03-31$9.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure10.8Research and development, Q2 FY2025, three months to 2025-06-30$10.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure9.6Research and development, Q3 FY2025, three months to 2025-09-30$9.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure13.1Research and development, Q4 FY2025, three months to 2025-12-31$13.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-10, accession 0001213900-26-025433. Derived: 12-month figure less the 9-month figure.Report this figure13.6Research and development, Q1 FY2026, three months to 2026-03-31$13.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure17.0Research and development, Q2 FY2026, three months to 2026-06-30$17.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure
Operating income$m(10.7)Operating income, Q3 FY2023, three months to 2023-09-30−$10.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figure(11.0)Operating income, Q4 FY2023, three months to 2023-12-31−$11.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-05, accession 0001213900-25-020368. Derived: 12-month figure less the 9-month figure.Report this figure(11.9)Operating income, Q1 FY2024, three months to 2024-03-31−$11.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure(10.7)Operating income, Q2 FY2024, three months to 2024-06-30−$10.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0001213900-25-073942.Report this figure(12.3)Operating income, Q3 FY2024, three months to 2024-09-30−$12.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure(14.3)Operating income, Q4 FY2024, three months to 2024-12-31−$14.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001213900-26-025433. Derived: 12-month figure less the 9-month figure.Report this figure(14.1)Operating income, Q1 FY2025, three months to 2025-03-31−$14.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure(16.6)Operating income, Q2 FY2025, three months to 2025-06-30−$16.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure(14.8)Operating income, Q3 FY2025, three months to 2025-09-30−$14.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure(19.1)Operating income, Q4 FY2025, three months to 2025-12-31−$19.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-10, accession 0001213900-26-025433. Derived: 12-month figure less the 9-month figure.Report this figure(19.6)Operating income, Q1 FY2026, three months to 2026-03-31−$19.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure(23.3)Operating income, Q2 FY2026, three months to 2026-06-30−$23.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(9.9)Net income, Q3 FY2023, three months to 2023-09-30−$9.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figure(10.2)Net income, Q4 FY2023, three months to 2023-12-31−$10.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-05, accession 0001213900-25-020368. Derived: 12-month figure less the 9-month figure.Report this figure(11.1)Net income, Q1 FY2024, three months to 2024-03-31−$11.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure(9.5)Net income, Q2 FY2024, three months to 2024-06-30−$9.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure(11.2)Net income, Q3 FY2024, three months to 2024-09-30−$11.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure(12.8)Net income, Q4 FY2024, three months to 2024-12-31−$12.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001213900-26-025433. Derived: 12-month figure less the 9-month figure.Report this figure(11.9)Net income, Q1 FY2025, three months to 2025-03-31−$11.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure(15.0)Net income, Q2 FY2025, three months to 2025-06-30−$15.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure(13.3)Net income, Q3 FY2025, three months to 2025-09-30−$13.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure(17.3)Net income, Q4 FY2025, three months to 2025-12-31−$17.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-10, accession 0001213900-26-025433. Derived: 12-month figure less the 9-month figure.Report this figure(17.8)Net income, Q1 FY2026, three months to 2026-03-31−$17.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure(21.7)Net income, Q2 FY2026, three months to 2026-06-30−$21.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure
Diluted EPS$ per share(0.87)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figurenot reported(0.97)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure(0.45)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0001213900-25-073942.Report this figure(0.50)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figurenot reported(0.29)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure(0.35)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure(0.31)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figurenot reported(0.31)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure(0.36)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure
Basic EPS$ per share(0.87)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.87 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figurenot reported(0.97)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.97 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure(0.45)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001213900-25-073942.Report this figure(0.50)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figurenot reported(0.29)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure(0.35)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure(0.31)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figurenot reported(0.31)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure(0.36)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure

Balance sheet

Cash and equivalents$17.1m, Q2 FY2026
Shareholders' equity$161.3m, Q2 FY2026
Protara Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m33.8Cash and equivalents, Q3 FY2023, at 2023-09-30$33.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-03, accession 0001213900-23-083013.Report this figure39.6Cash and equivalents, FY2023, at 2023-12-31$39.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-05, accession 0001213900-25-020368.Report this figure52.2Cash and equivalents, Q1 FY2024, at 2024-03-31$52.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-02, accession 0001213900-24-038757.Report this figure89.6Cash and equivalents, Q2 FY2024, at 2024-06-30$89.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-06, accession 0001213900-24-065380.Report this figure51.8Cash and equivalents, Q3 FY2024, at 2024-09-30$51.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figure163Cash and equivalents, FY2024, at 2024-12-31$162.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-10, accession 0001213900-26-025433.Report this figure91.5Cash and equivalents, Q1 FY2025, at 2025-03-31$91.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure31.5Cash and equivalents, Q2 FY2025, at 2025-06-30$31.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001213900-25-073942.Report this figure12.6Cash and equivalents, Q3 FY2025, at 2025-09-30$12.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure49.7Cash and equivalents, FY2025, at 2025-12-31$49.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure14.7Cash and equivalents, Q1 FY2026, at 2026-03-31$14.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure17.1Cash and equivalents, Q2 FY2026, at 2026-06-30$17.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure
Current assets$m77.8Current assets, Q3 FY2023, at 2023-09-30$77.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-03, accession 0001213900-23-083013.Report this figure68.7Current assets, FY2023, at 2023-12-31$68.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-05, accession 0001213900-25-020368.Report this figure57.9Current assets, Q1 FY2024, at 2024-03-31$57.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-02, accession 0001213900-24-038757.Report this figure92.2Current assets, Q2 FY2024, at 2024-06-30$92.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0001213900-24-065380.Report this figure85.1Current assets, Q3 FY2024, at 2024-09-30$85.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figure172Current assets, FY2024, at 2024-12-31$172.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-10, accession 0001213900-26-025433.Report this figure127Current assets, Q1 FY2025, at 2025-03-31$126.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure125Current assets, Q2 FY2025, at 2025-06-30$125.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0001213900-25-073942.Report this figure136Current assets, Q3 FY2025, at 2025-09-30$135.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure160Current assets, FY2025, at 2025-12-31$159.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure140Current assets, Q1 FY2026, at 2026-03-31$140.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure146Current assets, Q2 FY2026, at 2026-06-30$146.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure
Total assets$m88.5Total assets, Q3 FY2023, at 2023-09-30$88.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-03, accession 0001213900-23-083013.Report this figure79.0Total assets, FY2023, at 2023-12-31$79.0m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-05, accession 0001213900-25-020368.Report this figure68.1Total assets, Q1 FY2024, at 2024-03-31$68.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-02, accession 0001213900-24-038757.Report this figure102Total assets, Q2 FY2024, at 2024-06-30$101.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0001213900-24-065380.Report this figure94.1Total assets, Q3 FY2024, at 2024-09-30$94.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figure181Total assets, FY2024, at 2024-12-31$181.5m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-10, accession 0001213900-26-025433.Report this figure169Total assets, Q1 FY2025, at 2025-03-31$168.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure157Total assets, Q2 FY2025, at 2025-06-30$156.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0001213900-25-073942.Report this figure145Total assets, Q3 FY2025, at 2025-09-30$144.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure209Total assets, FY2025, at 2025-12-31$209.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure192Total assets, Q1 FY2026, at 2026-03-31$191.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure176Total assets, Q2 FY2026, at 2026-06-30$176.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure
Current liabilities$m6.8Current liabilities, Q3 FY2023, at 2023-09-30$6.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-03, accession 0001213900-23-083013.Report this figure6.1Current liabilities, FY2023, at 2023-12-31$6.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-05, accession 0001213900-25-020368.Report this figure5.5Current liabilities, Q1 FY2024, at 2024-03-31$5.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-02, accession 0001213900-24-038757.Report this figure5.6Current liabilities, Q2 FY2024, at 2024-06-30$5.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0001213900-24-065380.Report this figure8.6Current liabilities, Q3 FY2024, at 2024-09-30$8.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figure11.0Current liabilities, FY2024, at 2024-12-31$11.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-10, accession 0001213900-26-025433.Report this figure7.0Current liabilities, Q1 FY2025, at 2025-03-31$7.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure9.8Current liabilities, Q2 FY2025, at 2025-06-30$9.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0001213900-25-073942.Report this figure9.9Current liabilities, Q3 FY2025, at 2025-09-30$9.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure10.9Current liabilities, FY2025, at 2025-12-31$10.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure8.9Current liabilities, Q1 FY2026, at 2026-03-31$8.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure13.3Current liabilities, Q2 FY2026, at 2026-06-30$13.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure
Total liabilities$m11.5Total liabilities, Q3 FY2023, at 2023-09-30$11.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-03, accession 0001213900-23-083013.Report this figure10.6Total liabilities, FY2023, at 2023-12-31$10.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-05, accession 0001213900-25-020368.Report this figure9.7Total liabilities, Q1 FY2024, at 2024-03-31$9.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-02, accession 0001213900-24-038757.Report this figure9.6Total liabilities, Q2 FY2024, at 2024-06-30$9.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0001213900-24-065380.Report this figure12.3Total liabilities, Q3 FY2024, at 2024-09-30$12.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figure14.3Total liabilities, FY2024, at 2024-12-31$14.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-10, accession 0001213900-26-025433.Report this figure10.1Total liabilities, Q1 FY2025, at 2025-03-31$10.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure12.5Total liabilities, Q2 FY2025, at 2025-06-30$12.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0001213900-25-073942.Report this figure12.3Total liabilities, Q3 FY2025, at 2025-09-30$12.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure13.1Total liabilities, FY2025, at 2025-12-31$13.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure10.7Total liabilities, Q1 FY2026, at 2026-03-31$10.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure14.8Total liabilities, Q2 FY2026, at 2026-06-30$14.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m77.0Shareholders' equity, Q3 FY2023, at 2023-09-30$77.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figure68.3Shareholders' equity, FY2023, at 2023-12-31$68.3m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-10, accession 0001213900-26-025433.Report this figure58.4Shareholders' equity, Q1 FY2024, at 2024-03-31$58.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure92.1Shareholders' equity, Q2 FY2024, at 2024-06-30$92.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure81.8Shareholders' equity, Q3 FY2024, at 2024-09-30$81.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure167Shareholders' equity, FY2024, at 2024-12-31$167.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure158Shareholders' equity, Q1 FY2025, at 2025-03-31$158.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure144Shareholders' equity, Q2 FY2025, at 2025-06-30$144.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure132Shareholders' equity, Q3 FY2025, at 2025-09-30$132.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure196Shareholders' equity, FY2025, at 2025-12-31$196.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure181Shareholders' equity, Q1 FY2026, at 2026-03-31$181.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure161Shareholders' equity, Q2 FY2026, at 2026-06-30$161.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure

Cash flow

Operating cash flow−$15.4m, Q2 FY2026
Capital expenditure$24.0k, Q4 FY2025
Share repurchases$76.0k, Q1 FY2024
Protara Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(6.6)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$6.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001213900-24-096252. Derived: 9-month figure less the 6-month figure.Report this figure(8.7)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$8.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-05, accession 0001213900-25-020368. Derived: 12-month figure less the 9-month figure.Report this figure(10.4)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$10.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure(7.7)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$7.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0001213900-25-073942. Derived: 6-month figure less the 3-month figure.Report this figure(8.4)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$8.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001213900-25-107881. Derived: 9-month figure less the 6-month figure.Report this figure(9.3)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$9.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001213900-26-025433. Derived: 12-month figure less the 9-month figure.Report this figure(14.7)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$14.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure(12.3)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$12.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001213900-26-087508. Derived: 6-month figure less the 3-month figure.Report this figure(12.5)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$12.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001213900-25-107881. Derived: 9-month figure less the 6-month figure.Report this figure(17.0)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$16.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-10, accession 0001213900-26-025433. Derived: 12-month figure less the 9-month figure.Report this figure(21.3)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$21.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure(15.4)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$15.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001213900-26-087508. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$37.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0001213900-24-096252. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-05, accession 0001213900-25-020368. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$8.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001213900-25-107881. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-10, accession 0001213900-26-025433. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$44.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$22.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001213900-26-087508. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001213900-25-107881. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$24.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-10, accession 0001213900-26-025433. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Share repurchases$m0.0Share repurchases, Q3 FY2023, three months to 2023-09-30$27.0k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2023-11-03, accession 0001213900-23-083013. Derived: 9-month figure less the 6-month figure.Report this figure0.0Share repurchases, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2024-03-13, accession 0001213900-24-021982. Derived: 12-month figure less the 9-month figure.Report this figure0.1Share repurchases, Q1 FY2024, three months to 2024-03-31$76.0k. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2024-05-02, accession 0001213900-24-038757.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)61.01m, Q2 FY2026
Protara Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares11.3Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3011,265,475 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-03, accession 0001213900-23-083013.Report this figure11.3Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3111,303,869 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-02, accession 0001213900-24-038757.Report this figure11.3Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3011,307,842 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0001213900-24-065380.Report this figure11.3Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3011,347,887 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001213900-24-096252.Report this figure11.4Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3111,420,948 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0001213900-25-040811.Report this figure21.2Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3021,233,163 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0001213900-25-073942.Report this figure22.3Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3022,329,772 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure40.7Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3140,707,937 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure42.3Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3042,270,855 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure42.3Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3042,272,104 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001213900-25-107881.Report this figure57.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3157,538,833 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001213900-26-055463.Report this figure61.0Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3061,006,766 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure

Shares outstanding: 59.10mShares outstanding, period not labelled, at 2026-08-0759,095,488 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001213900-26-087508.Report this figure at Aug 7, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. Listed shows no prices and gives no investment advice.